Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify

Executive Summary

Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.

Advertisement

Related Content

Alkermes Sees Payer Savings Opportunity With Aristada Approval
Otsuka Seeks First Approval For Drug Tablet With Ingestible Sensor
Digital Age: Otsuka Sets Sights On Abilify Combo Tablet With Sensor
J&J’s Invega Trinza Is First Three-Month Atypical Antipsychotic
Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak
BIO 2014 Tuesday Round-Up: AstraZeneca Looking Forward, Not Back
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
J&J's Invega Sustenna To Launch "Soon"; Payers Want Compliance Data
J&J CNS Studies Show Awareness Of CER And Broader Databases
FDA Discounts Advisory Panel’s Advice, Says Lilly’s Depot Zyprexa “Not Approvable”

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel